JPRN-jRCTs021200007已完成未知
Efficacy and Safety of Mirogabalin for the Treatment as Add-On to NSAIDs in patients with Peripheral Neuropathic Pain caused by Lumbar Spinal Stenosis : Multi-institutional, randomized, open, parallel-design and interventional Study
ikaido Takuya0 个研究点目标入组 220 人开始时间: 2020年6月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 220
研究概览
简要总结
From this study, it was indicated that NSAIDs and mirogabalin combination therapy showed efficacy to the Lumbar Spinal Stenosis patients to whom pain management by NSAIDs monotherapy had been insufficient. Though it was necessary to pay attention to the occurrence of somnolence, dizziness, and so on when adding mirogabalin to NSAIDs, no difference was seen about frequency of AE occurrence in comparison with previous study, and no new concern was found about safety.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients who have lower limb pain caused by nerve root-type Lumber Spinal Stenosis and can be judged that more than 3 months have passed since the occurrence of the pain has started. (Refer to Procedure for diagnosis of nerve root-type Lumber Spinal Stenosis for details.)
- •2) Patients who is administrated NSAIDS at the enrollment and have not changed dose for more than 4 weeks before the enrollment.
- •3) Patients with more 40mm of VAS for lower limb pain at informed consent and the enrollment.
- •4) Patients with 20 years old or older at the enrollment.
- •5) Patients who are able to understand the procedure of the clinical study, answer a question appropriately and give their voluntary written consent to participate in the study.
排除标准
- •1) Patients who used prohibited drugs within 7 days before the enrollment of the study.
- •2) Patients who changed administration and dosage of limited drugs within 4 weeks before the enrollment of the study.
- •3) Patients who have severe pain caused by symptoms except for Lumber Spinal Stenosis and have difficulty being evaluated for the study.
- •4) Patients with cauda equina type or mixed-type Lumber Spinal Stenosis.
- •5) Patients who have past history of lumber spine surgery
- •6) Patients who have complication of cancer, infectious disease and fracture at the enrollment.
- •7) Patients who have past history of hypersensitivity to ingredients of Mirogabalin.
- •8) Patients who have difficulty participating in the study due to severe complication of liver disease, kidney disease and heart disease.
- •9) Pregnancy patients or patients who have possibility of pregnancy.
- •10) Patients with creatinine clearance less than 30mL/min by Cockroft-Gault Equation at enrollment
- •11) Patients with more than 11 points or 10 points in physician version of the Brief Scale for Psychiatric Problems in Orthopaedic Patients (BS POP) and also 15 points in patient version of BS POP.
- •12) Patients who are inappropriate for participation in the study for othe reason in the opinion of the investigator or sub-investigator.
- •13) Previous treatment with Mirogabalin.
研究者
相似试验
已完成
不适用
ADMIT-NeP Studyeuropathic painJPRN-jRCTs071200053agayasu Takeshi128
进行中（未招募）
不适用
Miro-CensPeripheral Neuropathic Pain caused by Cervical Spondylotic RadiculopathyJPRN-jRCTs031210629Hirai Takashi140
已完成
不适用
MIROP StudyPeripheral Neuropathic PainJPRN-jRCTs031190113Kimura Yoshiyuki152
招募中
不适用
The efficacy and safety of mirogabalin for neuropathic paineuropathic painJPRN-UMIN000036855Kajiki Hospital100
已完成
不适用
The efficacy and safety of Mirogabalin for chronic pain derived from neuropathic paiChronic pain, Neuropathic painJPRN-UMIN000037216TT Medical Center Tokyo Department of Pain clinic257